Morgan Stanley Protalix Bio Therapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 173,071 shares of PLX stock, worth $181,724. This represents 0.0% of its overall portfolio holdings.

Number of Shares

173,071

Previous 249,500 30.63%

Holding current value

$181,724

Previous $444,000 50.9%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.22 - $1.82 $93,243 - $139,100	-76,429 Reduced 30.63%	173,071 $218,000
Q4 2023 Feb 13, 2024	BUY	$1.34 - $1.85 $67,891 - $93,730	50,665 Added 25.48%	249,500 $444,000
Q3 2023 Nov 15, 2023	BUY	$1.49 - $2.02 $91,691 - $124,306	61,538 Added 44.82%	198,835 $330,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $110,242 - $185,206	55,121 Added 67.08%	137,297 $274,000
Q1 2023 May 15, 2023	BUY	$1.37 - $2.16 $101,323 - $159,751	73,959 Added 900.07%	82,176 $172,000

Q2 2022 Oct 27, 2022	SELL	$1.02 - $1.56 $16,014 - $24,492	-15,700 Reduced 65.64%	8,217 $9,000
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.56 $16,014 - $24,492	-15,700 Reduced 65.64%	8,217 $9,000
Q1 2022 Oct 27, 2022	BUY	$0.81 - $1.17 $12,717 - $18,369	15,700 Added 191.07%	23,917 $25,000
Q1 2022 May 13, 2022	SELL	$0.81 - $1.17 $1.03 Million - $1.48 Million	-1,269,046 Reduced 98.15%	23,917 $25,000
Q4 2021 Feb 14, 2022	SELL	$0.81 - $1.33 $803,610 - $1.32 Million	-992,112 Reduced 43.42%	1,292,963 $1.08 Million
Q3 2021 Nov 15, 2021	BUY	$1.31 - $1.87 $2.99 Million - $4.27 Million	2,285,075 New	2,285,075 $3.04 Million

Others Institutions Holding PLX

# of Institutions

Shares Held

9.27M

Call Options Held

40.6K

Put Options Held

10.1K

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $52.2M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account